Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor

VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.